Legal & General Group Plc Raises Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Legal & General Group Plc raised its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 209.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 572,263 shares of the company's stock after buying an additional 387,225 shares during the quarter. Legal & General Group Plc owned about 0.26% of Hims & Hers Health worth $13,841,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HIMS. Invesco Ltd. grew its stake in Hims & Hers Health by 613.9% in the fourth quarter. Invesco Ltd. now owns 1,277,026 shares of the company's stock valued at $30,878,000 after purchasing an additional 1,098,148 shares in the last quarter. Polymer Capital Management US LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $381,000. Sierra Summit Advisors LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $484,000. Quadrant Capital Group LLC bought a new position in Hims & Hers Health during the fourth quarter worth $53,000. Finally, Envestnet Asset Management Inc. grew its stake in shares of Hims & Hers Health by 139.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 78,686 shares of the company's stock valued at $1,903,000 after buying an additional 45,791 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $28.50, for a total value of $330,058.50. Following the transaction, the chief financial officer now owns 118,960 shares of the company's stock, valued at $3,390,360. This represents a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 27,098 shares of the firm's stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $30.08, for a total value of $815,107.84. Following the transaction, the chief executive officer now owns 27,918 shares in the company, valued at $839,773.44. The trade was a 49.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 843,271 shares of company stock worth $32,021,671 over the last three months. 17.71% of the stock is owned by insiders.

Hims & Hers Health Trading Down 5.3 %

HIMS traded down $1.45 during trading on Monday, hitting $25.79. 2,251,317 shares of the company traded hands, compared to its average volume of 15,330,366. The company has a market cap of $5.73 billion, a PE ratio of 58.74 and a beta of 1.65. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The stock's 50-day simple moving average is $37.26 and its two-hundred day simple moving average is $30.79.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

HIMS has been the topic of several research reports. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price objective on the stock. Leerink Partners upped their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Bank of America increased their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a report on Tuesday, March 18th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Finally, Piper Sandler upped their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $38.25.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.